# Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial

> **NCT04390022** · PHASE2 · COMPLETED · sponsor: **Clinica Universidad de Navarra, Universidad de Navarra** · enrollment: 24 (actual)

## Conditions studied

- Covid-19
- Coronavirus Infection
- SARS-CoV-2 Infection

## Interventions

- **DRUG:** Ivermectin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04390022
- **Lead sponsor:** Clinica Universidad de Navarra, Universidad de Navarra
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-31
- **Primary completion:** 2020-09-17
- **Final completion:** 2020-10-09
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04390022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04390022, "Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04390022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*